← All trials
NCT00114530
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2005
- Primary completion
- Apr 1, 2016
- Completion date
- Apr 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 75
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of KentuckyOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Presbyterian/St. Luke's Medical Center, DenverStudy chair
- Duke UniversityStudy chair
- University of California, Los AngelesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.